Vitamin D in blood and risk of prostate cancer: Lessons from the Selenium and vitamin E cancer prevention trial and the prostate cancer prevention trial

Research output: Contribution to journalReview article

11 Scopus citations


The effects of blood levels of 25-hydroxyvitamin D (25-OHD) on the risk of total, low-, and high-grade prostate cancer were examined in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) and the Prostate Cancer Prevention Trial (PCPT). In the SELECT study, plasma 25-OHD levels were associated with a linear decrease in prostate cancer risk for high-grade cancers in African American men and an apparent "U"-shaped effect in other men. The "U-shaped" curve may reflect detection bias. In the PCPT study, in which detection bias was minimized, serum 25-OHD levels were associated with a linear decrease in the risk of high-grade prostate cancers. The results from these large prevention trials support the hypothesis that circulating levels of 25-OHD decrease the risk of clinically relevant prostate cancers.

Original languageEnglish (US)
Pages (from-to)1447-1449
Number of pages3
JournalCancer Epidemiology Biomarkers and Prevention
Issue number8
StatePublished - Aug 2014


ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this